Jacob Aligo

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

Retrieved on: 
Friday, October 21, 2022
Degenerative disease, SAN, Pharmacology, Doctor of Philosophy, Therapy, Liver disease, Efficiency, Antibody, Liver cancer, Hepatitis B virus, American Association, Association, CEO, Fatty liver disease, Safety, Poster, CAM, American Association for the Study of Liver Diseases, CHB, Drug development, HBsAg, HAP, MBA, Private Securities Litigation Reform Act, NASH, HBeAg, GLOBE, PD-L1, Institute of Liver and Biliary Sciences, CAMS, Hepatitis, Security (finance), Sirna Therapeutics, AAV, Viral hepatitis, Board, U.S. Securities and Exchange Commission, HBV, Terminology, AASLD, Science, EC50, Pharmacodynamics, HBcAg, THR, Patient, RNA, Nasdaq, Sirna, Hyperlipidemia, Toxicity, Liver, Forward-looking statement, PK, COVID-19, Pharmaceutical industry, Vaccine, Pharmacokinetics, Jacob Aligo

All posters, which cover drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH), will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.

Key Points: 
  • All posters, which cover drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH), will be available on the Aligos website at Scientific Presentations & Conferences following the conclusion of the conference.
  • The Liver Meeting 2022 will showcase the breadth and depth of Aligos portfolio of potential treatments for CHB and the continued progress in our NASH program, said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos.
  • Data showing the effects of ALG-000184 on HBV DNA, RNA and HBsAg levels are discussed in the poster.
  • First, HAP CAM-1s were shown to induce hepatitis B virus (HBV) core protein (HBc) aggregation and hepatocyte apoptosis in HBc-expressing cells.

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

Retrieved on: 
Wednesday, October 19, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Therapy, Liver disease, CHB, Drug development, Hepatitis, Security (finance), Fatty liver disease, Nasdaq, Private Securities Litigation Reform Act, NASH, Viral hepatitis, GLOBE, Forward-looking statement, Terminology, Pharmaceutical industry, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

Retrieved on: 
Tuesday, October 18, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Therapy, Liver disease, Conference, Vaccine, Severe acute respiratory syndrome coronavirus 2, CHB, Drug development, Hepatitis, MBA, Security (finance), Program, Fatty liver disease, Entrepreneurship, Nasdaq, Private Securities Litigation Reform Act, NASH, Trial of the century, Company, Doctor of Philosophy, Viral hepatitis, CEO, GLOBE, Forward-looking statement, Terminology, COVID-19, Pharmaceutical industry, Jacob Aligo

In the presentation, Aligos will review its progress towards the development of broadly-acting, orally available small molecule protease inhibitors to address COVID-19, regardless of the strain.

Key Points: 
  • In the presentation, Aligos will review its progress towards the development of broadly-acting, orally available small molecule protease inhibitors to address COVID-19, regardless of the strain.
  • Rapid evolution of new SARS-CoV-2 variants and the presence of multiple other coronaviruses indicate the need for broadly acting antivirals across all coronaviruses.
  • The SARS-CoV-2 3CL protease (3CLpro) is a clinically validated target and is conserved across coronaviruses.
  • Aligos will review the discovery efforts towards oral pan-coronaviral 3CLpro inhibitors, culminating in the discovery and advancement of ALG-097558.

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

Retrieved on: 
Friday, October 14, 2022
Degenerative disease, SAN, Institute of Liver and Biliary Sciences, U.S. Securities and Exchange Commission, Doctor of Philosophy, Therapy, Liver disease, CHB, Drug development, HBsAg, Hepatitis, MBA, Security (finance), Fatty liver disease, Nasdaq, Sirna Therapeutics, NASH, Private Securities Litigation Reform Act, Sirna, Viral hepatitis, Board, Pharmacokinetics, CEO, Safety, GLOBE, Forward-looking statement, Terminology, COVID-19, Vaccine, Pharmaceutical industry, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, an siRNA targeting the production of hepatitis B surface antigen (HBsAg), was initiated in healthy volunteers in Study ALG-125755-501 (NCT05561530).

Key Points: 
  • Drugs in this class have generally been well tolerated and have consistently lowered HBsAg levels with more convenient dosing frequencies compared to other injectable HBsAg lowering agents.
  • This is an important first step in the clinical evaluation of the safety, pharmacokinetics, and antiviral activity of ALG-125755, said Matthew W. McClure, M.D., Chief Medical Officer of Aligos.
  • We plan to evaluate single ascending doses across multiple cohorts of healthy volunteers in Q4 2022.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Retrieved on: 
Wednesday, September 28, 2022
ASO, University, Hepatitis, Therapy, Doctor of Philosophy, COVID-19, Sirna, Institute of Liver and Biliary Sciences, County, Oligonucleotide, NASH, Publication, Liver disease, CHB, HBV, Degenerative disease, Forward-looking statement, U.S. Securities and Exchange Commission, CEO, Hepatitis B virus, MBA, Terminology, Nasdaq, Fatty liver disease, Superior court, Viral hepatitis, Private Securities Litigation Reform Act, Drug development, SAN, Biotechnology, Security (finance), Janssen, GLOBE, Management, Jacob Aligo

The response further outlines and documents that all work was performed by Aligos employees after leaving Janssen Biopharma.

Key Points: 
  • The response further outlines and documents that all work was performed by Aligos employees after leaving Janssen Biopharma.
  • The counterclaims against Janssen allege that Janssen has engaged in unfair competition and promissory fraud.
  • Aligos co-founders, Lawrence M. Blatt, Ph.D., MBA, and Leonid Beigelman, Ph.D., joined Aligos in filing the counterclaims.
  • The facts are on Aligos side, and we will continue to defend ourselves from the baseless allegations made by Janssen.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, CEO, GLOBE, R, Investment, European Association for the Study of the Liver, Board, Security (finance), Center, Patient, KU Leuven, CTA, Protease, Drug design, CAM, G&A, Fatty liver disease, Infection, HBsAg, Degenerative disease, Terminology, ASO, CHB, Institute of Liver and Biliary Sciences, EASL, Congress, SAN, Safety, Doctor of Philosophy, Nasdaq, Pharmacokinetics, Medical research, HBeAg, PF-07321332, Forward-looking statement, EC50, NASH, Therapy, COVID-19, Cell, Program, Drug development, Â, Severe acute respiratory syndrome coronavirus 2, Rega Institute for Medical Research, Association, Sirna, Liver disease, Viral hepatitis, Hepatitis, Research, MBA, CD3, Private Securities Litigation Reform Act, Pharmaceutical industry, Vaccine, Jacob Aligo, Liver

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.
  • In the second quarter, we continued to make strong progress in advancing our drug candidates and discovery programs, said Lawrence Blatt, PhD, MBA, CEO and Chairman of the Board at Aligos.
  • ALG-000184 (CAM-2): Enrollment of HBeAg positive subjects in 28-day and 12-week cohorts evaluating various dose levels is ongoing.
  • We plan to share data from HBeAg positive cohorts at a scientific conference in Q4 2022.

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

Retrieved on: 
Wednesday, July 27, 2022
GLOBE, Degenerative disease, U.S. Securities and Exchange Commission, Liver disease, Forward-looking statement, SAN, Hepatitis, Private Securities Litigation Reform Act, NASH, Fatty liver disease, Therapy, CHB, Institute of Liver and Biliary Sciences, Drug development, Viral hepatitis, Security (finance), Nasdaq, Terminology, Pharmaceutical industry, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the companys second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets.
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

Retrieved on: 
Monday, July 25, 2022
DNA, GLOBE, Degenerative disease, U.S. Securities and Exchange Commission, Liver disease, CEO, SAN, Hepatitis, Forward-looking statement, Private Securities Litigation Reform Act, NASH, Fatty liver disease, Board, Therapy, CHB, COVID-19, Institute of Liver and Biliary Sciences, Drug development, Viral hepatitis, MBA, Security (finance), Patient, Nasdaq, Doctor of Philosophy, HBV, Terminology, RNA, Pharmaceutical industry, Vaccine, HBeAg, Jacob Aligo

HBeAg-positive subjects are known to have much higher baseline HBV DNA and RNA levels compared to HBeAg-negative subjects and are consequently harder to treat.

Key Points: 
  • HBeAg-positive subjects are known to have much higher baseline HBV DNA and RNA levels compared to HBeAg-negative subjects and are consequently harder to treat.
  • Based on the current rate of enrollment, we plan to share data from this important cohort at a scientific conference in Q4 2022.
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European As

Retrieved on: 
Wednesday, June 22, 2022
Association, RNA, Therapy, EASL, Hyperlipidemia, MBA, Safety, Institute of Liver and Biliary Sciences, CHB, ILC, CEO, Liver, Pharmacokinetics, Sirna, HBsAg, Hepatitis B virus, CAM, DNA, European Association for the Study of the Liver, GLOBE, Nasdaq, NASH, Fatty liver disease, Patient, Doctor of Philosophy, HBV, Vaccine, Pharmaceutical industry, Jacob Aligo, HBeAg

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company is presenting two posters showcasing preliminary Phase 1 data from its capsid assembly modulator (CAM) program in CHB and its thyroid hormone receptor-beta (THR-b) agonist in nonalcoholic steatohepatitis (NASH) at the European Association for the Study of the Liver Digital International Liver Congress™ 2022 (EASL ILC 2022). ILC 2022 is being held on June 22 - 26 at the ExCeL London Exhibition Centre in London, UK.

Key Points: 
  • The company is also presenting nonclinical data from two other drug classes within Aligos CHB portfolio: small interfering RNA (siRNA) and a small molecule PD-L1 inhibitor.
  • The posters will be available on the Scientific Presentation and Publications page in the Presentations section of Aligos website at www.aligos.com .
  • Our team is also proud to announce the first clinical data from our THR-b agonist in NASH, said Lawrence Blatt, Ph.D., MBA, Chairman and CEO of Aligos.
  • We also plan to soon initiate a longer-term study evaluating ALG-000184 in combination with nucleos(t)ide analog therapy in HBeAg positive CHB.

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

Retrieved on: 
Monday, May 23, 2022
Fatty liver disease, Jefferies, U.S. Securities and Exchange Commission, NASH, Degenerative disease, Hepatitis, Therapy, Viral hepatitis, CHB, COVID-19, Liver disease, Forward-looking statement, Terminology, Drug development, Institute of Liver and Biliary Sciences, Risk management, Jacob Aligo

The Aligos management team will also participate in investor 1x1 meetings during the conference.

Key Points: 
  • The Aligos management team will also participate in investor 1x1 meetings during the conference.
  • Please contact your Jefferies representative to schedule one-on-one meetings with Aligos during the conference.
  • Aligos Therapeutics, Inc.is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.